926027
NanoFabTX™-DOTAP Lipid Mix
for synthesis of cationic (DOTAP) liposomes
Sinónimos:
Drug delivery, LNP, Microfluidics, NanoFab reagent kit, Nanoformulation, Nanoparticle
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
UNSPSC Code:
12162002
NACRES:
NA.23
Productos recomendados
Quality Level
storage temp.
−20°C
General description
NanoFabTx™-DOTAP Lipid Mix includes reagents and optimized protocols with step-by-step instructions for synthesizing cationic liposomes for drug delivery research applications. The modification of liposomes with the cationic lipid, DOTAP, have numerous advantages such as their large-DNA incorporation, high transfection efficiency, and low toxicity. Liposome-based formulations are widely used for drug delivery applications and enable improved therapeutic efficacy of a range of drug types including small molecules, nucleic acids, proteins, and peptides.
Comprehensive protocols for liposome synthesis are included:
The microfluidics protocol included with this product uses NanoFabTx™ device kits (911593). These kits come with the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).
Comprehensive protocols for liposome synthesis are included:
- A lipid film hydration and extrusion protocol.
- A microfluidics protocol using commercial platforms or syringe pumps.
The microfluidics protocol included with this product uses NanoFabTx™ device kits (911593). These kits come with the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).
Application
NanoFabTx™-DOTAP Lipid Mix is a ready-to-use nanoformulation blend for the synthesis of cationic DOTAP-functionalized liposomes. This kit enables users to encapsulate a wide variety of therapeutic drug molecules for targeted or extended drug delivery without the need for lengthy trial-and-error optimization. NanoFabTx™ kits provide an easy-to-use toolkit for encapsulating a variety of therapeutics in nanoparticles, microparticles, or liposomes. Drug encapsulated particles synthesized with the NanoFabTx™ kits are suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, and vaccine delivery.
Features and Benefits
- A ready-to-use nanoformulation blend for the synthesis of cationic liposomes
- Step-by-step protocols (extrusion or microfluidic) developed and tested by our formulation scientists
- Flexible synthesis tools to create uniform and reproducible liposomes
- Optimized to make liposomes around 100 nm with low polydispersity
- DOTAP surface-functionalized allows for targeting ligand conjugation to enable targeted drug delivery
Legal Information
NANOFABTX is a trademark of Sigma-Aldrich Co. LLC
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
Elija entre una de las versiones más recientes:
Certificados de análisis (COA)
Lot/Batch Number
¿No ve la versión correcta?
Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Which polymers can make nanoparticulate drug carriers long-circulating?
Torchilin VP, et al.
Advanced Drug Delivery Reviews, 16, 141-155 (1995)
Which polymers can make nanoparticulate drug carriers long-circulating?
Torchilin V P, et al.
Advanced Drug Delivery Reviews, 16, 141-155 (1995)
D Papahadjopoulos et al.
Proceedings of the National Academy of Sciences of the United States of America, 88(24), 11460-11464 (1991-12-15)
The results obtained in this study establish that liposome formulations incorporating a synthetic polyethylene glycol-derivatized phospholipid have a pronounced effect on liposome tissue distribution and can produce a large increase in the pharmacological efficacy of encapsulated antitumor drugs. This effect
Daryl C Drummond et al.
Cancer research, 66(6), 3271-3277 (2006-03-17)
Liposome formulations of camptothecins have been actively pursued because of the potential for significant pharmacologic advantages from successful drug delivery of this important class of anticancer drugs. We describe nanoliposomal CPT-11, a novel nanoparticle/liposome construct containing CPT-11 (irinotecan) with unprecedented
L D Mayer et al.
Biochimica et biophysica acta, 1025(2), 143-151 (1990-06-27)
Studies from this laboratory (Mayer et al. (1986) Biochim. Biophys. Acta 857, 123-126) have shown that doxorubicin can be accumulated into liposomal systems in response to transmembrane pH gradients (inside acidic). Here, detailed characterizations of the drug uptake and retention
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico